<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01624194</url>
  </required_header>
  <id_info>
    <org_study_id>SU-12132011-8827</org_study_id>
    <nct_id>NCT01624194</nct_id>
  </id_info>
  <brief_title>Intranasal Oxytocin Treatment for Social Deficits in Children With Autism</brief_title>
  <official_title>Double-blind, Randomized, Placebo Controlled Trial of Intranasal Oxytocin Treatment for Social Deficits in Children With Autism.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autism is a pervasive developmental disorder characterized by core deficits in social
      behavior and communication, and the presence of repetitive or stereotyped behaviors. It is
      one of three recognized disorders in the autism spectrum which affects an estimated 1 in 88
      children in the United States. At present, pharmacotherapies target only associated features
      of autism, with no effective drug treatments for the social impairments. Several lines of
      evidence now suggest that the neuropeptide oxytocin (OT) may be an effective treatment for
      the core social deficits in autism. Here we will test the effects of twice daily intranasal
      OT (24 IU) over a 4-week period for enhancing social deficits in male and female children
      aged 6-12 years with autism. This research has high potential to lead to the development of
      more effective treatments and earlier interventions for children with autism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In recent years, the neuropeptide oxytocin (OT) has been implicated in a wide range of social
      behaviors including attachment bonds, emotion recognition, eye gaze to social cues, and
      memory for social information. Social impairments represent one of the most intractable
      features of autism, and evidence now suggests that OT biology is dysregulated in individuals
      with this disorder. The central aim of the research outlined here is to test whether OT
      administration to children with autism increases their quality and quantity of social
      interactions and enhances their ability to process emotional and social information. Findings
      from initial single-dose OT administration studies in teenaged and adult males with autism
      have shown improvement in some aspects of social functioning, but replication and extension
      to well-controlled treatment trials with younger male and female subjects is necessary to
      evaluate effectiveness. We therefore aim to investigate the effect of intranasal OT on social
      cognition and behavior immediately following a single-dose (24IU) and following a 4-week
      period of OT (24IU BID) administration in a sample of 50 subjects with autism aged 6 to 12
      years. The primary outcome for this study is change in social behavior, as determined by
      parent ratings on the Social Responsiveness Scale (SRS) after the 4-week treatment period.
      Secondary outcomes are changes in functioning on laboratory-based measures of social behavior
      and cognition following single-dose and 4-week OT administration. Research in a small study
      sample (N=13) also identified treatment responders and non-responders to a single-dose of OT.
      Thus, we also aim to identify biological and cognitive and behavioral variables (i.e.,
      pretreatment levels of social functioning and pretreatment plasma hormone levels) that may
      influence treatment response efficacy in our larger study sample. On completion of the 4-week
      treatment period all subjects will have the option of participating in another 4-week
      double-blind trial in which they will be switched to the alternate nasal spray to that which
      they previously received. They will then undergo a fourth and final assessment time-point
      using the same testing procedures as outlined above on completion of the 4-week dosing. By
      providing subjects with the option of participating in a second 4-week treatment trial, all
      subjects will have an opportunity to receive the active oxytocin nasal spray. We also will be
      able to examine any ongoing effects of oxytocin treatment in the group receiving placebo
      during the second 4-week administration period. Subjects not willing to take part in the
      second trial will exit the study and will be referred to their treating physician.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in parent rated Social Responsiveness Scale (SRS) scores during treatment.</measure>
    <time_frame>4-weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parent rated Dosage Record Treatment Emergent Symptom Scale (DOTES) scores during treatment.</measure>
    <time_frame>Single-dose, 4-week, 8-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in heart rate, blood pressure, body temperature, and body mass index.</measure>
    <time_frame>Single-dose, 4-week, 8-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Global Impression (CGI) scores during treatment.</measure>
    <time_frame>4-week, 8-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in parent rated Social Responsiveness Scale (SRS) scores during treatment.</measure>
    <time_frame>8-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in parent rated Aberrant Behavior Checklist (ABC) scores during treatment.</measure>
    <time_frame>4-week, 8-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in parent rated Spence Children's Anxiety Scale (SCAS) during treatment.</measure>
    <time_frame>4-week, 8-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Vineland Adaptive Behavior Scales - Social and Communication subscales during treatment.</measure>
    <time_frame>4-weeks, 8-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory based facial emotion recognition abilities during treatment.</measure>
    <time_frame>Single-dose, 4-week, 8-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory based eye-gaze to social cues during treatment.</measure>
    <time_frame>Single-dose, 4-week, 8-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Reading the Mind in the Eyes Test, child version (RMET-child) scores during treatment.</measure>
    <time_frame>Single-dose, 4-week, 8-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory based social mimicry abilities during treatment.</measure>
    <time_frame>Single-dose, 4-week, 8-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Developmental NEuroPSYchological Assessment (NEPSY-II) Social Perception and Memory for Faces &amp; Names subscales scores during treatment.</measure>
    <time_frame>Single-dose, 4-week, 8-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma oxytocin, vasopressin, and cortisol levels during treatment.</measure>
    <time_frame>4-week, 8-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in parent rated Repetitive Behavior Scale Revised (RBS-R) scores during treatment.</measure>
    <time_frame>4-week, 8-week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>Oxytocin nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prior to randomization, all subjects will participate in a 1-week open-label placebo lead-in trial. Each subject will be administered the placebo nasal spray at Stanford University and then their parent will continue administering the nasal spray to the subject for 1 week at home. Each subject will then be randomly assigned either to the active group or to the placebo (stratified by gender) and will be given the appropriate nasal spray bottle and their parents will be responsible for administering 3 puffs per nostril (4 IU/puff) to their child for a total dose of 24 IU oxytocin or placebo twice daily (BID; morning and evening) for 4-weeks. On completion of this 4-week treatment trial subjects will have the option of participating in a second double-blind trial in which they will be assigned to the alternate nasal spray, to that which they received during the first 4-week trial, for an additional 4-week period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo nasal spray bottles will be prepared by adding all of the ingredients used in the Syntocinon nasal sprays with the exception of the concentrated oxytocin solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin nasal spray</intervention_name>
    <description>24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice daily for 4-weeks.</description>
    <arm_group_label>Oxytocin nasal spray</arm_group_label>
    <other_name>SyntocinonÂ® Nasal Spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
    <arm_group_label>Placebo nasal spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medically healthy outpatients between 6 and 12 years of age (cut off 12 years and 11
             months)

          -  Intelligence Quotient &gt; 40

          -  Diagnosis of autism spectrum disorder based on the Autism Diagnostic Interview -
             Revised, Autism Diagnostic Observation Schedule, and DSM-IV criteria

          -  Clinical Global Impression severity rating of 4 or higher

          -  Care provider who can reliably bring subject to clinic visits, provide trustworthy
             ratings, and interacts with the subject on a regular basis

          -  Stable medications for at least 4 weeks

          -  No planned changes in psychosocial interventions during the trial

          -  Willingness to provide blood samples.

        Exclusion Criteria:

          -  Diagnostics and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) diagnosis
             of schizophrenia, schizoaffective disorder, or psychotic disorder

          -  Regular nasal obstruction or nosebleeds

          -  Active medical problems: unstable seizures, significant physical illness (e.g.,
             serious liver, renal, or cardiac pathology)

          -  Sensitivity to preservatives (in particular E 216, E 218, and chlorobutanol
             hemihydrate)

          -  A genetic abnormality (e.g., Fragile X Syndrome)

          -  Significant hearing or vision impairments

          -  Habitually drinks large volumes of water

          -  Pregnancy, breastfeeding, or child birth within the last 6 months

          -  Sexually active females not using a reliable method of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Y Hardan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen J Parker, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2012</study_first_submitted>
  <study_first_submitted_qc>June 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2012</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Antonio Hardan</investigator_full_name>
    <investigator_title>Associate Professor of Child Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 20, 2017</submitted>
    <returned>October 19, 2017</returned>
    <submitted>January 17, 2018</submitted>
    <returned>February 13, 2018</returned>
    <submitted>May 3, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

